Literature DB >> 12651279

Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia.

Melchior Lauten, Girmay Asgedom, Karl Welte, Martin Schrappe, Martin Stanulla.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12651279

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.

Authors:  Jose Claudio C Rocha; Cheng Cheng; Wei Liu; Shinji Kishi; Soma Das; Edwin H Cook; John T Sandlund; Jeffrey Rubnitz; Raul Ribeiro; Dario Campana; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

2.  PharmGKB summary: methotrexate pathway.

Authors:  Torben S Mikkelsen; Caroline F Thorn; Jun J Yang; Cornelia M Ulrich; Deborah French; Gianluigi Zaza; Henry M Dunnenberger; Sharon Marsh; Howard L McLeod; Kathy Giacomini; Mara L Becker; Roger Gaedigk; James Steven Leeder; Leo Kager; Mary V Relling; William Evans; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

3.  Thymidylate synthase and methionine synthase polymorphisms are not associated with susceptibility to childhood acute lymphoblastic leukemia in Kurdish population from Western Iran.

Authors:  Zohreh Rahimi; Zainab Ahmadian; Reza Akramipour; Asad Vaisi-Raygani; Ziba Rahimi; Abbas Parsian
Journal:  Mol Biol Rep       Date:  2011-06-05       Impact factor: 2.316

Review 4.  Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.

Authors:  Lin Mei; Evelena P Ontiveros; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Blood Rev       Date:  2015-01-10       Impact factor: 8.250

5.  Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?

Authors:  Phuong Thu Vu Hoang; Jérôme Ambroise; Anne-France Dekairelle; Jean-François Durant; Valentina Butoescu; Vu Luan Dang Chi; Nghia Huynh; Tan Binh Nguyen; Annie Robert; Christiane Vermylen; Jean-Luc Gala
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 6.  Pharmacogenetics in acute lymphoblastic leukemia.

Authors:  Meyling H Cheok; Nicolas Pottier; Leo Kager; William E Evans
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

Review 7.  Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?

Authors:  Sunitha Kodidela; Pradhan Suresh Chandra; Biswajit Dubashi
Journal:  Eur J Clin Pharmacol       Date:  2013-12-27       Impact factor: 2.953

Review 8.  The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.

Authors:  Shoshana Rudin; Marcus Marable; R Stephanie Huang
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-04-06       Impact factor: 7.691

9.  Influence of Folate-Related Gene Polymorphisms on High-Dose Methotrexate-Related Toxicity and Prognosis in Turkish Children with Acute Lymphoblastic Leukemia.

Authors:  Burcu Yazıcıoğlu; Zühre Kaya; Sezen Güntekin Ergun; Ferda Perçin; Ülker Koçak; İdil Yenicesu; Türkiz Gürsel
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.